Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$79.33 USD

79.33
5,569,039

-2.48 (-3.03%)

Updated Aug 5, 2024 04:00 PM ET

After-Market: $79.34 +0.01 (0.01%) 6:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Valeant (VRX) Down on Q4 Earnings Miss, Issues Drab '18 View

Valeant (VRX) announced disappointing results in the fourth quarter. The outlook for 2018 was dismal too, which disappointed investors.

    Sweta Killa headshot

    Stocks to Buy & Avoid If Trump Slaps Import Tariffs

    The import curbs could lead to few winners but a number of losers from various corner of the equity space if the tariff is slapped.

      Lilly's Verzenio Wins FDA Nod for First Line Breast Cancer

      Lilly's (LLY) new advanced breast cancer treatment Verzenio (abemaciclib) gains FDA approval in first-line setting.

        Clovis (CLVS) Q4 Loss Narrower Than Expected, Revenues Miss

        Clovis (CLVS) witnesses narrower year-over-year loss in the fourth quarter. However, the company's revenues miss estimates. Rubraca sales lower.

          Pharma Stock Roundup: AZN's Imfinzi Gets 2nd FDA Nod, MRK to Buy Australian Firm

          Key announcements this week included the FDA approval for a second indication of AstraZeneca's (AZN) Imfinzi and an acquisition offer by Merck (MRK).

            Is a Beat in the Cards for Perrigo (PRGO) in Q4 Earnings?

            Perrigo's (PRGO) product purchases and launches in the Rx segment might boost sales in the coming quarters.

              FDA Accepts Acorda's NDA for Parkinson's Disease Candidate

              FDA accepts Acorda's (ACOR) new drug application (NDA) for its parkinson's disease candidate, Inbrija and it also set an action date of Oct 5, 2018.

                Ionis Out-Licenses Second Candidate to AstraZeneca, Earns $30M

                Ionis Pharmaceuticals (IONS) out-licenses Generation 2.5 antisense drug to AstraZeneca under a strategic collaboration agreement.

                  AstraZeneca's (AZN) Imfinzi Gets FDA Nod for Label Expansion

                  Data shows that AstraZeneca's (AZN) Imfinzi improved PFS by more than 11 months in comparison to placebo in the concerned patient population.

                    Ironwood (IRWD) Beats Estimates in Q4 Earnings, Stock Up

                    Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the fourth quarter. Demand for Linzess continues to rise.

                      Swarup Gupta headshot

                      Foreign Stock Roundup: RDS.A & AZN Impress, NVO & BABA Disappoint

                      Losses on Wall Street and falling bond yields weighed on global markets this week.

                        Job Data Upbeat, Tech Companies Post Modest Q4 Earnings

                        Job Data Upbeat, Tech Companies Post Modest Q4 Earnings

                          Mark Vickery headshot

                          Jobs Report Hits 200K, Unemployment 4.1%; Plus More Q4 Earnings

                          While this 200K number is higher than the analyst consensus of roughly 180K (analyst for months have been expecting 180K new jobs), it is below the ADP (ADP) payroll report released Wednesday morning.

                            AstraZeneca (AZN) Beats on Q4 Earnings, Guides for 2018

                            AstraZeneca (AZN) beats earnings estimates in fourth quarter on higher product revenues.

                              Merck vs. Sanofii: Which Stock Is Better Pre-Q4 Earnings?

                              With Merck and Sanofi scheduled to report on Feb 2 and Feb 27, respectively, this may be a good time to figure out which of these is a better stock.

                                Allergan (AGN) to Report Q4 Earnings: What's in the Cards?

                                While Allergan's (AGN) Q4 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products will hurt sales.

                                  Alkermes Submits NDA for Depression Candidate to the FDA

                                  Alkermes (ALKS) files a new drug application to the FDA for ALKS 5461's effective use in the adjunctive treatment of major depressive disorder (MDD).

                                    Can Merck (MRK) Deliver a Positive Surprise in Q4 Earnings?

                                    Merck's (MRK) new products like Keytruda and Bridion are likely to drive sales in the fourth quarter. However, headwinds remain in the form of genericization of key drugs and increasing competition.

                                      AstraZeneca's Triple Combo COPD Inhaler Positive in Phase III

                                      AstraZeneca (AZN) announces positive top-line results from the phase III KRONOS study on the triple combination therapy PT010 for severe COPD patients.

                                        Merus' Antibody Candidate in Phase II Breast Cancer Study

                                        Merus (MRUS) initiates a phase II study to evaluate its most advanced pipeline candidate in advanced breast cancer.

                                          Lilly (LLY) to Report Q4 Earnings: What's in the Cards?

                                          Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

                                            Infinity Provides Update on Lead Candidate, Issues 2018 View

                                            Infinity (INFI) announces the achievement of some development milestones for its lead pipeline candidate- IPI-549 and issued financial guidance for 2018.

                                              Is a Beat in the Cards for AbbVie (ABBV) in Q4 Earnings?

                                              Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company to an earnings beat in Q4.

                                                The Zacks Analyst Blog Highlights: AbbVie, Merck & Co. and AstraZeneca

                                                The Zacks Analyst Blog Highlights: AbbVie, Merck & Co. and AstraZeneca

                                                  3 Large Cap Pharma Stocks to Beat Earnings This Quarter

                                                  The fourth-quarter outlook for Pharma stocks looks bright.